In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Omrix nets $31.9mm with IPO

Executive Summary

Omrix Biopharmaceuticals (biosurgical and immunotherapy products) netted $31.9mm through the initial public offering of 3.4mm common shares at $10 each. The company had initially given the shares a price range of $15-17.
Deal Industry
  • Medical Devices
  • Pharmaceuticals
  • Medical Devices
    • Biomaterials
    • Surgical Equipment & Devices
      • Surgical Sealants
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

UsernamePublicRestriction

Register